Patents by Inventor Ian Livey
Ian Livey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11305000Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: January 19, 2018Date of Patent: April 19, 2022Assignees: Brookhaven Science Associates, LLC, The Research Foundation of State University of New York, Baxalta Incorporated, Baxalta GmbHInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20180296656Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: January 19, 2018Publication date: October 18, 2018Applicants: BROOKHAVEN SCIENCE ASSOCIATE, LLC, RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORKInventors: Brian A. Crowe, Ian Livey, Maria O'rourke, Michael Schwendinger, John J Dunn, Benjamin J Luft
-
Patent number: 9895434Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: February 22, 2016Date of Patent: February 20, 2018Assignees: Research Foundation of the State University of New York, Brookhaven Science Associates, LLCInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20160235830Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: February 22, 2016Publication date: August 18, 2016Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Patent number: 9334311Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: November 12, 2013Date of Patent: May 10, 2016Assignees: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Patent number: 9303073Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: November 12, 2013Date of Patent: April 5, 2016Assignees: BAXALTA INCORPORATED, BAXALTA GMBH, Research Foundation of the State University of New York, Brookhaven Science Associates, LLCInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Patent number: 9023367Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: July 11, 2013Date of Patent: May 5, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: P. Noel Barrett, Gerald Aichinger, Brian A. Crowe, Ian Livey, Nina Wressnigg
-
Publication number: 20140141030Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: November 12, 2013Publication date: May 22, 2014Applicants: BAXTER INTERNATIONAL INC., Brookhaven Science Associates, LLC, Research Foundation of the State University of New York, BAXTER HEALTHCARE SAInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20140141029Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: November 12, 2013Publication date: May 22, 2014Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Publication number: 20140030284Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: July 11, 2013Publication date: January 30, 2014Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: P. Noel Barrett, Gerald Aichinger, Brian A. Crowe, Ian Livey, Nina Wressnigg
-
Patent number: 8623376Abstract: The invention relates to the development of chimeric OpsA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: May 13, 2011Date of Patent: January 7, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A., Research Foundation for the State University of New York, Brookhaven Science Associates, LLCInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Patent number: 8623375Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: May 13, 2011Date of Patent: January 7, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Publication number: 20120020973Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: May 13, 2011Publication date: January 26, 2012Applicants: BAXTER INTERNATIONAL INC., Brookhaven Sciences Associates, LLC, Research Foundation of the State University of New York, BAXTER HEALTHCARE S.A.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20110293652Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: May 13, 2011Publication date: December 1, 2011Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Patent number: 6872550Abstract: A novel approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains of B. burgdorferi are grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.Type: GrantFiled: April 29, 1994Date of Patent: March 29, 2005Assignee: Baxter Vaccine AGInventors: Ian Livey, Brian Crowe, Friedrich Dorner
-
Patent number: 6486130Abstract: A novel approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains of B burgdorferi are grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.Type: GrantFiled: June 27, 1996Date of Patent: November 26, 2002Assignee: Baxter Vaccine AGInventors: Ian Livey, Brian Crowe, Friedrich Dorner
-
Patent number: 6221363Abstract: An effective immunogen against Lyme borreliosis in mammals comprises homogenous B. burgdorferi pC protein and a physiologically-acceptable excipient.Type: GrantFiled: June 25, 1992Date of Patent: April 24, 2001Assignee: Baxter AktiengesellschaftInventors: Ian Livey, Friedrich Dorner
-
Patent number: 5530103Abstract: A method of purifying B. burgdorferi proteins comprising the steps of (a) disrupting a B. burgdorferi cell and fractionating the disrupted cell into membrane and cytoplasmic components; (b) resuspending the membrane component in a non-denaturing detergent thereby producing a solubilized protein and an insolubilized material and then separating said solubilized protein from said insolubilized material; (c) subjecting the solubilized protein to ion-exchange chromatography so as to produce protein fractions; and (d) assaying the protein fractions to identify those fractions which contain proteins of interest wherein the purified proteins of interest are in a biologically active form suitable for use in vaccines, is disclosed.Type: GrantFiled: March 12, 1993Date of Patent: June 25, 1996Assignee: Immuno AktiengesellschaftInventors: Ian Livey, Friedrich Dorner